XLXue Lei

Xue Lei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xue Lei has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Alan Perez-Rathke

    Center for Bioinformatics and Quantitative Biology & Richard and Loan Hill Department of Bioengineering, University of Illinois at Chicago, Chicago, IL, 60612, USA

    1 shared publication
  • Boshen Wang

    University of Illinois at Chicago, Center for Bioinformatics and Quantitative Biology

    1 shared publication
  • Heng Sun

    Department of Oncology First Affiliated Hospital, Heilongjiang University of Chinese Medicine Harbin Heilongjiang China

    1 shared publication
  • Jia-Xin Yang

    Clinical Nursing Teaching and Research Section, the Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China; National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, PR China

    1 shared publication
  • Jie Liang

    Boinformatics Program Center for Bioinformatics and Quntitative Biology Richard and Loan Hill Department of Biomedical Engineering University of Illinois at Chicago 60612 Chicago USA

    1 shared publication
  • Lijia Zhang

    Ethics Committee Office First Affiliated Hospital, Heilongjiang University of Chinese Medicine Heilongjiang Harbin China

    1 shared publication

Latest Publications

  • Astragaloside II enhanced sensitivity of ovarian cancer cells to cisplatin via triggering apoptosis and autophagy

    by Lijia Zhang, Ye Liu, Xue Lei, Xiaowai Liu, Heng Sun, Songjiang Liu

    Cisplatin (DDP) based chemotherapy occurs a reduced therapeutic effect on the later treatment of ovarian cancer (OC) due to DDP resistance. Astragaloside II (ASII), a natural product extracted from Radix Astragali, has shown promising anticancer effects. However, the effects of ASII on OC have not been clarified. In this study, we found that ASII inhibited cell growth and promoted cell apoptosis of DDP‐resistant OC cells in vitro and in vivo. Further study showed that ASII downregulated multidrug resistance‐related protein MDR1 and cell cycle‐related protein Cyclin D1 and PCNA, and also upregulated apoptosis‐related protein leaved PRAP and cleaved caspase‐3. In addition, ASII induced autophagy, characterized by upregulation of LC3II expression, downregulation of p62 expression, and elevation of LC3 punctuation, may be associated with inhibition of the AKT/mTOR signaling pathway. Moreover, the messenger RNA‐sequencing was used to identify potential molecules regulated by ASII. In conclusion, these findings indicated that ASII increased sensitivity of DDP in the treatment of OC.


  • Open Access

    SeqMapPDB: A Standalone Pipeline to Identify Representative Structures of Protein Sequences and Mapping Residue Indices in Real-Time at Proteome Scale

    by Boshen Wang, Xue Lei, Wei Tian, Alan Perez-Rathke, Yan-Yuan Tseng, Jie Liang

    Motivation: 3D structures of proteins provide rich information for understanding their biochemical roles. Identifying the representative protein structures for protein sequences is essential for analysis of proteins at proteome scale. However, there are technical difficulties in identifying the representative structure of a given protein sequence and providing accurate mapping of residue indices. Existing databases of mapping between structures and sequences are usually static that are not suitable for studying proteomes with frequent gene model revisions. They often do not provide reliable and consistent representative structures that maximizes sequence coverage. Furthermore, proteins isomers are usually not properly resolved. Results: To overcome these difficulties, we have developed a computational pipeline called SeqMapPDB to provide high-quality representative PDB structures of given sequences. It provides mapping to structures that fully cover the sequences when available, or to the set of partial non-overlapping structural domains that maximally cover the query sequence. The residue indices are accurate mapped and isomeric proteins are resolved. SeqMapPDB is efficient and can rapidly carry out proteome-wide mapping to the selected version of reference genomes in real-time. Furthermore, SeqMapPDB provides the flexibility of a stand-alone pipeline for large scale mapping of in-house sequence and structure data. Availability: Our method is available at https://bitbucket.org/lianglabuic/seqmappdb with GNU GPL license.